Ginkgo Bioworks (NYSE: DNA) officer sells shares to cover taxes after RSU vesting

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported routine equity compensation activity involving restricted stock units. On April 16, 2026, he exercised RSUs to acquire a total of 743 shares of Class A Common Stock at a conversion price of $0.00 per share, reflecting vesting of previously granted awards.

On April 17, 2026, Coen sold 324 shares of Class A Common Stock at an average price of $7.952 per share. According to the disclosure, these shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock and RSUs and are not considered discretionary trades. After these transactions, he directly holds 50,268 shares of Class A Common Stock.

Insights

Equity compensation and insider trading analyst

Routine RSU vesting with sell-to-cover tax sale; limited signaling value.

Officer Steven P. Coen had 743 RSUs convert into Class A shares at $0.00 per share, representing normal vesting under Ginkgo Bioworks Holdings, Inc.’s equity incentive plans. These transactions increase his direct share holdings as part of ongoing compensation.

The subsequent sale of 324 shares at $7.952 per share is explicitly described as a "sell to cover" for tax withholding obligations, not a discretionary decision to reduce exposure. Following the transactions, Coen holds 50,268 shares, so the net-sell amount is small relative to his position.

Given the tax-driven nature and modest scale of the sale, the activity is best viewed as routine administration of equity awards rather than a change in sentiment. Future company filings may provide additional context on ongoing RSU vesting schedules and remaining unvested awards.

Insider Trade Summary

Net Seller: 324 shares ($2,576)

Net Sell 5 txns

Insider Coen Steven P.

Role See remarks

Sold 324 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	324	$7.952	$3K
Exercise	Restricted Stock Units	587	$0.00	--
Exercise	Restricted Stock Units	156	$0.00	--
Exercise	Class A Common Stock	587	$0.00	--
Exercise	Class A Common Stock	156	$0.00	--

Holdings After Transaction: Class A Common Stock — 50,268 shares (Direct, null); Restricted Stock Units — 7,644 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter. The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.

Key Figures

Shares sold for tax withholding: 324 shares at $7.952 RSUs converted to shares: 743 shares at $0.00 Shares held after transactions: 50,268 shares +2 more

5 metrics

Shares sold for tax withholding 324 shares at $7.952 Sell-to-cover transaction on April 17, 2026

RSUs converted to shares 743 shares at $0.00 RSU exercises on April 16, 2026

Shares held after transactions 50,268 shares Direct Class A holdings following Form 4 report

RSU balance for one grant 7,644 RSUs Total RSUs following transaction for 587‑unit grant

RSU balance for another grant 3,599 RSUs Total RSUs following transaction for 156‑unit grant

Key Terms

Restricted Stock Units, sell to cover, equity incentive plans, tax withholding obligations, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"The Issuer's equity incentive plans allow the Issuer to require that satisfaction"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

net-sell financial

""netBuySellDirection": "net-sell""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coen Steven P.

(Last) (First) (Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	04/16/2026		M(1)		587	A	(1)	50,436	D
Class A Common Stock	04/16/2026		M(1)		156	A	(1)	50,592	D
Class A Common Stock	04/17/2026		S(2)		324	D	$7.952	50,268	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	04/16/2026		M(1)			587	(3)	(3)	Class A Common Stock	587	(1)	7,644	D
Restricted Stock Units	(1)	04/16/2026		M(1)			156	(4)	(4)	Class A Common Stock	156	(1)	3,599	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

3. The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.

4. The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.

Remarks:

Chief Financial Officer

	/s/ Karen Tepichin, Attorney-in-Fact	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Steven P. Coen report at Ginkgo Bioworks (DNA)?

Steven P. Coen reported RSU vesting and a small tax-related share sale. He converted 743 restricted stock units into Class A shares, then sold 324 shares to cover tax withholding obligations. After these transactions, he directly holds 50,268 shares of Ginkgo Bioworks Class A Common Stock.

How many Ginkgo Bioworks (DNA) shares did Steven P. Coen sell and at what price?

Steven P. Coen sold 324 shares of Ginkgo Bioworks Class A Common Stock. The reported average sale price was $7.952 per share. The disclosure states these shares were sold solely to cover tax withholding obligations linked to vesting equity awards, not as discretionary open-market selling.

Were Steven P. Coen’s Ginkgo Bioworks (DNA) share sales discretionary trades?

No. The filing states the 324 shares sold were to cover tax withholding obligations from vesting restricted stock and RSUs. The company’s equity incentive plans allow a “sell to cover” mechanism, so these transactions are characterized as administrative rather than discretionary investment decisions by Coen.

How many Ginkgo Bioworks (DNA) shares does Steven P. Coen own after these Form 4 transactions?

After the reported transactions, Steven P. Coen directly holds 50,268 shares of Ginkgo Bioworks Class A Common Stock. This total reflects RSU conversions increasing his holdings, partially offset by a 324‑share sale executed to satisfy tax withholding obligations on the vested equity awards.

What restricted stock unit activity did Ginkgo Bioworks (DNA) disclose for Steven P. Coen?

The Form 4 shows Coen had 743 restricted stock units convert into Class A shares at a $0.00 conversion price. Footnotes explain each RSU represents a contingent right to one share, with vesting schedules that include initial vesting on May 1, 2024, followed by monthly installments thereafter.

Why does the Ginkgo Bioworks (DNA) Form 4 mention a sell-to-cover tax withholding transaction?

The filing explains that the 324 shares sold by Steven P. Coen were used to fund tax withholding obligations tied to vesting stock awards. Ginkgo Bioworks’ equity incentive plans permit the company to require this “sell to cover” approach, clarifying the sale’s administrative, non‑discretionary nature.